Evidence map›Paper›PMID 41415066›Full record

ArticleAmerican journal of translational research2025

Synergistic antitumor efficacy of CIK cells combined with PD-1 inhibitors in nasopharyngeal carcinoma.

Jing Chen, Tumaer Sailihan, Yanhong Chen, Suzhen Xv, Jiong Qian, Xinyi Shen, Hangjing Yang, Pan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing ChenDepartment of Medical Oncology, The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang, China.
Tumaer SailihanLaboratory Animal Center of Zhejiang University Hangzhou 310058, Zhejiang, China.
Yanhong ChenLaboratory Animal Center of Zhejiang University Hangzhou 310058, Zhejiang, China.
Suzhen XvDepartment of Medical Oncology, The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang, China.
Jiong QianDepartment of Medical Oncology, The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang, China.
Xinyi ShenLaboratory Animal Center of Zhejiang University Hangzhou 310058, Zhejiang, China.
Hangjing YangDepartment of Pathology, The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang, China.
Pan ZhangLaboratory Animal Center of Zhejiang University Hangzhou 310058, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the synergistic anti-tumor effects and underlying mechanisms of combining cytokine-induced killer (CIK) cell therapy with programmed death 1 (PD-1) blockade in the treatment of nasopharyngeal carcinoma (NPC).

methodsCIK cells were generated from peripheral blood mononuclear cells (PBMCs) of healthy donors. The combinatorial effects were assessed

results

conclusionsCombined CIK cell therapy and PD-1 blockade demonstrated significant synergistic anti-tumor activity against NPC by enhancing cytotoxicity, activating key signaling pathways, and remodeling the tumor immune microenvironment. This strategy represents a promising therapeutic approach for NPC.

Indexed as

CIKcombinationnasopharyngeal carcinomaPD-1signal pathway

Identifiers

PMID41415066
PMCPMC12709348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.